Adeno-associated virus antibody profiles in newborns, children, and adolescents

Clin Vaccine Immunol. 2011 Sep;18(9):1586-8. doi: 10.1128/CVI.05107-11. Epub 2011 Jul 20.

Abstract

Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / blood*
  • Child
  • Child, Preschool
  • Dependovirus / classification
  • Dependovirus / genetics
  • Dependovirus / immunology*
  • Genetic Therapy
  • Genetic Vectors / immunology
  • Humans
  • Infant, Newborn
  • Parvoviridae Infections / epidemiology*
  • Parvoviridae Infections / immunology
  • Parvoviridae Infections / virology
  • Prevalence
  • Serotyping
  • Transduction, Genetic

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral